Bortezomib Intermediate

• Post Date:

  Mar 06,2018

• Expiry Date:

  Mar 06,2019

• Detailed Description:

  Cas No. :179324-87-9 Specs:purity above 99%
  Payment Method: T/T; L/C
  Appearance: white or white-off powder
  Application: Bortezomib api intermediates and impurities
  DeliveryTime: 3-4 days as soon as order is made
  Package: aluminum foil or as customer requiredProduction
  Capacity: 2 Kilogram/Month
  Purity: above 99%
  Storage: stored in dry and clean place
  Transportation: Air Sea Courier as Fedex, DHL, EMS
  LimitNum: 5 GramRelated
  Substances: complies
  Valid Period: 2 years
  8 years manufacturing experience: customers' trust

• CAS Registry Number:

  179324-87-9

• Synonyms:

  ;(1R)-(S)-Pinanediol 1-Ammonium trifluoroacetate-3-Methylbutane-1-BORONATE;(R)-BoroLeu-(+)-Pinanediol-CF3COOH;(R)-BoroLeu-(+)-Pinanediol-CF3CO2H;2,5-diamino-4,6-dihydroxy pyrimidine Hydrochloride;(R)-BoroLeu-(+)-Pinanediol-CF3 COOH;(1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butan-1-amine trifluoroacetate (1:1);(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate;(aR,3aS,4S,6S,7aR)-hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl-4,6-methano-1,3,2-benzodioxaborole-2-methanamine 2,2,2-trifluoroacetate;(R)-3-Methyl-1-((3As,4S,6S,7Ar)-3A,5,5-Trimethylhexahydro-4,6-Methanobenzo[D][1,3,2]Dioxaborol-2-Yl)Butan-1-Amine 2,2,2-Trifluoroacetate;(1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethythexahydro-4,6-methano-1,3,2-benzodioxa-borol-2-yl]butan-1-amine trifluoroacetate;(aR,3aS,4S,6S,7aR)-Hexahydro-3a,8,8-trimethyl-alpha-(2-methylpropyl)-;(1R)-(1S,2S,3R,5S)-Pinanediol-1-ammoniumtrifluoroacetate-3-methyl butane-1-boronate;

• Molecular Formula:

  C₁₇H₂₉BF₃NO₄

• Molecular Weight:

  379.2226696

• Molecular Structure:

  

• Company:

  Genen Pharmaceuticals Co.,Ltd     [ China ]        

• Contact:

  Ada Wang

• Tel:

  +86 15625232582

• Fax:

  +86 755 61112308

• Email:

  sales@genen-pharma.com